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Introduction: In order to obtain premarket approval for medical products derived from human cells or
tissues in the United States (US), the European Union (EU), and Japan, data from clinical trials are
typically required to evaluate product efﬁcacy and safety. Clinical investigators or study sponsors often
face challenges when designing clinical trials on human cells and tissue products with the goal of
obtaining premarket approval owing to the unique characteristics of products in this category. The
methods used to administer, infuse and transplant these products vary more widely than the methods
used for pharmaceuticals. In addition, ﬁnal product quality may vary depending on the product source,
i.e., patients or donors. These products are generally intended to treat intractable and rare diseases or
injuries; therefore, it may not be possible to collect a sufﬁcient number of cases and enrollment may be a
long process. Moreover, since the technology for product development in this category is relatively new,
knowledge and experience from previous studies are limited.
Methods: The key elements for the design of clinical trials to determine product efﬁcacy were identiﬁed
by examining clinical trial designs for approving products. Review reports for approved products from
regulatory authorities in the US and Japan as well as the European public assessment reports in the EU
were analyzed.
Results: For one product approved in the US, Dermagraft®, Bayesian statistics were used to evaluate
product efﬁcacy, instead of traditional (frequentist) statistics. Based on the statistical guidance for clinical
trials recently issued by the US Food and Drug Administration, statistical analyses including Bayesian
statistics are key elements in the design of clinical trials for products based on human cells and tissues.
New regulations regarding human cells and tissue products have recently been implemented in Japan,
including conditional and time-limited approval for regenerative medicine products. In these cases,
Bayesian statistics are a promising alternative approach to support product development.
Conclusions: Our results emphasize the beneﬁt of considering cogitating statistical methods, such as
Bayesian statistics, when designing clinical trials for regulatory purposes.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Medical products derived from human cells and tissues are
unambiguously distinct from chemically synthesized drugs and
medical devices, and are regulated separately by the authorities;
they are categorized as “human cells, tissues, and cellular and
tissue-based products (HCT/Ps)” in the United States (US) [1],
“advanced therapy medicinal products (ATMPs)” in the European
Union (EU) [2], and “regenerativemedicine products” in Japan [3,4].sting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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on human cells and tissue products with the goal of obtaining
premarket approval, they often face challenges, particularly when
assessing product efﬁcacy, owing to unique characteristics of
products in the category. There is wider variation in the methods
used to administer, infuse and transplant these products than in
those for pharmaceuticals. In addition, the quality of the ﬁnal
product may vary depending on the source, i.e., patients or donors.
These products are generally intended to treat intractable and rare
diseases or injuries; therefore, it may not be possible to collect a
sufﬁcient number of cases and study enrollment may be very slow.
These features of cells and tissue products that may impact clinical
study design were summarized in a guidance of the US Food and
Drug Administration (FDA) [5]. Moreover, since the technology
used for products in the category is relatively new, knowledge and
experience from previous studies are limited.
In an analysis of the study designs of clinical trials on human
cells and tissue products approved in the US, the EU, and Japan, we
found that Dermagraft®, which utilizes allogeneic cells, was
approved in the US based on pivotal study data that was analyzed
using Bayesian statistics. In this pivotal study, an interim analysis,
which is considered an adaptive design, was utilized, and these
statistical approaches were important for the acceptance of the
clinical efﬁcacy of the product.
Bayesian statistics are an alternative to traditional statistics,
i.e., frequentist statistics, and have recently been employed in
clinical trials to evaluate pharmaceuticals, not only in Phase III
studies, but also in Phase I and II studies [6]. In some cases,
Bayesian statistics can be used to reduce the sample size and to
apply mid-course adjustments to a trial design, or to stop a trial,
shortening the study duration [7]. Moreover, Bayesian statistics
have been regarded as a useful statistical method for clinical trials
since the middle of the last decade because the approach is ideally
suited to adapting to information accrued during a trial, poten-
tially allowing for smaller and more informative trials [8]. In the
pivotal Dermagraft® study, an interim analysis was utilized in the
decision to stop the study when a targeted number of cases was
reached, and to determine the necessity for additional enrollment.
The purpose of an interim analysis is to stop a trial early if a suf-
ﬁcient difference between groups is obtained to conclude that an
intervention is effective or harmful [9]. Early stopping may allow
subjects in the placebo arm as well as those not in the trial to
receive a beneﬁcial treatment sooner. In contrast, when severe
side effects are encountered, early stopping of the trial may pre-
vent unnecessary harm. Early stopping may also save money and
facilitate the rapid reporting and translation of results to clinical
practice [9].
The FDA recently issued a guidance to the study design of
clinical trials for medical devices, named “Guidance for the Use of
Bayesian Statistics in Medical Device Clinical Trials” [7]. Although
some additional conditions are required to utilize Bayesian statis-
tics; 1) prior information should be discussed with the FDA prior to
the initiation of a study, and 2) indications of the device may be
impacted by modiﬁcations at the interim analysis, the Bayesian
framework has several unique advantages over its frequentist
counterpart. Traditional statistical methods only use information
from previous studies at the design stage. In contrast, Bayesian
statistics formally incorporate prior information gathered before,
during, and outside of the trial [10]. Furthermore, many clinical
trials are conducted over an extended period of time, and it is
desirable to frequently monitor the interim results of such trials in
order to promote more rapid decisions when sufﬁcient evidence is
obtained. Bayesian methods allow for more frequent monitoring
and interim decision making during trials [10]. Based on the
concept outlined in the FDA guidance as well as the successfulexample, Bayesian statistics should be considered in the design of
studies to evaluate human cells and tissue products.
No such guidance documents for statistical methods used in
clinical trials have been introduced by regulatory authorities in the
EU and Japan; this initiative is unique to the US. Statistical in-
ferences are based on mathematical models of experiments,
including clinical trials. Moreover, in Japan, new regulations for
human cells and tissue products were introduced in 2014, in which
conditional and time-limited approval pathways speciﬁc to the
product category are included [4].
In the current study, we performed a comparative investigation
of the guidance documents for statistical methods for clinical trials
in the US, the EU, and Japan, and summarized of a unique case in
which Bayesian statistics and an interim analysis were successfully
applied during a trial design.
2. Methods
Guidance documents describing statistical methods for clinical
trials were obtained from appropriate regulatory websites in the
US [11], the EU [12], and Japan [13]. Approval information for
human cells and tissue products was obtained from the websites
of the relevant regulatory authorities in the US (Biologics [14],
Premarket approval (PMA) [15], Humanitarian Device Exemption
(HDE) [16]), the EU [17], and Japan [18] at the end of June, 2016.
According to the deﬁnitions and research methods used in pre-
vious studies [19,20], products utilizing either autologous or
allogeneic human cells or tissues were selected from review re-
ports in the US and Japan and from European public assessment
reports in the EU. The study design for each product was identiﬁed
from the clinical data section in each report. Individual review
reports or European public assessment reports of the products
approved in the US, the EU, and Japan were obtained from the
following sources: the FDA websites for Carticel™ [21], Epicel®
[22], Provenge® [23], Laviv® [24], Dermagraft-TCTM [25], Apri-
graf™/Garftskin [26], Composite Cultured Skin [27], Orcel™ [28],
Dermagraft® [29], Gintuit [30], Hemacord [31], HPC/Cord blood
[32], Ducord [33], Allocord [34], HPC/Cord blood [35], and HPC
cord blood [36]; European Medical Agency (EMA) websites for
ChondroCelect® [37], MACI [38], Provenge [39], and Holoclar [40];
and Pharmaceuticals and Medical Devices Agency (PMDA) web-
sites for JACC [41], JACE [42], Temcell® HS Inj. [43] and Heart-
Sheet® [44]. Information related to clinical trials for the approved
products, such as that described at ClinicalTrials.gov [45], was also
analyzed.
3. Results
3.1. Guidance on clinical trial design
In the US, several guidance documents related to clinical trial
design for medical devices and human cells and tissue products
have recently been issued by the FDA. “Guidance for the Use of
Bayesian Statistics in Medical Device Clinical Trials” was issued by
the Center for Devices and Radiological Health (CDRH) and the
Center for Biologics Evaluation and Research (CBER) of the FDA on
February 5, 2010 [7]. This guidance document clariﬁes the utiliza-
tion of Bayesian statistics, and includes a strong recommendation
for consultation with the FDA when planning a study protocol. It is
speciﬁcally applicable to medical device clinical trials, including
products derived from human cells and tissues. CDRH and CBER
also issued the draft guidance document “Adaptive Designs for
Medical Device Clinical Studies” on May 18, 2015 [46]. This docu-
ment addresses adaptive designs for medical device clinical trials
and is applicable to pre-market medical device submission,
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novo submissions, Humanitarian Device Exemption (HDE) appli-
cations, and Investigational Device Exemption (IDE) submissions
[46]. More recently, CBER of the FDA issued a guidance document
for industry titled “Considerations for the Design of Early-Phase
Clinical Trials of Cellular and Gene Therapy Products” in June
2015 [5]. The guidance document was issued to assist sponsors and
investigators with the design of early-phase clinical trials for
cellular therapy and gene therapy products, and to provide current
recommendations regarding clinical trials in which the primary
objectives are the initial assessment (most Phase I and some Phase
II) of safety, tolerability, or feasibility of the administration of
investigational products [5].
In the EU, “Statistical Principles for Clinical Trials”was published
by the EMA [47]. These guidelines were developed at the Interna-
tional Conference on the Harmonization of Technical Requirements
for the Registration of Pharmaceuticals for Human Use (ICH), and
apply to clinical trials on “medicinal products” or drugs. In Japan,
the Ministry of Health and Welfare issued guidelines as a notiﬁ-
cation titled “Statistical Principles for Clinical Trials” [48], trans-
lated from the ICH guidelines introduced in the EU described above.
The following statement describes the application of Bayesian
statistics in the ICH guidelines: ‘“…because the predominant ap-
proaches to the design and analysis of clinical trials have been
based on frequentist statistical methods, the guidance largely refers
to the use of frequentist methods when discussing hypothesis
testing and/or conﬁdence intervals. This should not be taken to
imply that other approaches are not appropriate: the use of
Bayesian and other approaches may be considered when the rea-
sons for their use are clear and when the resulting conclusions are
sufﬁciently robust.”
3.2. Approval and clinical study design for human cells and tissue
products and associated clinical designs
According to the deﬁnitions presented in previous studies
[19,20], 24 products derived from human cells or tissues for
clinical treatments were identiﬁed as of the end of June 2016.
Clinical trial information (e.g., study design, sample size, primary
efﬁcacy endpoints, and results) obtained for products is summa-
rized in Table 1. Six products, Hemacord [31], HPC/Cord blood [32],
Ducord [33], Allocord [34], HPC/Cord blood [35], and HPC cord
blood [36] were excluded owing to a lack of clinical studies or
trials that solely involved the target product; hence, information
for these products is not available in the review reports. When we
analyzed the review reports for products in the US and Japan as
well as the European public assessment reports for products in the
EU, we found that a reasonably large number of cases were typi-
cally enrolled and primary endpoints were evaluated statistically,
except for the humanitarian device exemption (HDE) products in
the US and most approved products in Japan. As described in
Section 3.3, product information for Dermagraft® was investi-
gated in great detail because the clinical study design was unique
from a regulatory standpoint owing to its use of an interim
analysis and Bayesian statistics. The study was initiated in
December 1998 and completed in March 2000, and the study
results, which were evaluated in the review by the FDA, were
published in 2003 [49].
3.3. Dermagraft®
Dermagraft® is a cryopreserved human ﬁbroblast-derived
dermal substitute; it is composed of ﬁbroblasts, an extracellular
matrix, and a bioabsorbable scaffold. The product is manufactured
from human ﬁbroblast cells derived from newborn foreskin tissue.The application of the product was reviewed by CDRH and
approved in September 28, 2001 [29].
Dermagraft® was intended for use in the treatment of full-
thickness diabetic foot ulcers with a duration of greater than six
weeks and those that extend through the dermis, but without
tendon, muscle, joint capsule, or bone exposure. Dermagraft® is
recommended for use in conjunction with standard wound care
regimens and in patients that have adequate blood supply to the
involved foot.
The sponsor conducted a total of ﬁve trials to evaluate the
product, and the data obtained in all trials were used for assurance
of the safety and efﬁcacy of the product in the treatment of full-
thickness diabetic foot ulcers with a duration of greater than six
weeks by product review. Pivotal studies were conducted twice to
evaluate product efﬁcacy, Pivotal I and II (Table 1), and data from
the second pivotal study, Pivotal II, were used to conﬁrm the
product efﬁcacy in the authority review for product approval. In
both pivotal studies, the superiority of Dermagraft® with the con-
ventional treatment over the conventional treatment alone as the
control was evaluated. The primary efﬁcacy endpoint for both
pivotal studies was the same, i.e., complete wound closure by 12
weeks. In the ﬁrst pivotal study, or Pivotal I, the primary endpoint
was challenged for comparisons with the control treatment, as
deﬁned in the protocol; however, no conclusion was reached
regarding the superiority of the product with respect to the control
treatment in the review report, even though “42 out of the 109
evaluable patients from the Dermagraft® group (39%) and 40 out of
the 126 evaluable patients from the control group (32%) reached
complete wound closure by 12 weeks.”
The second pivotal study, or Pivotal II, had a similar study
design to Pivotal I (i.e., a randomized control study in which pa-
tients were treated with Dermagraft® plus conventional therapy,
or conventional therapy alone). The completion of wound closure
by 12 weeks was evaluated as the primary efﬁcacy endpoint, as in
Pivotal I. In this trial, the original total sample size was calculated
based on a two-group Fisher's exact test with a 0.0294 one-sided
signiﬁcance level and at least 80% power, requiring an enrollment
of up to 330 patients for the Dermagraft® and control groups (1:1)
in the initial study design (Fig. 1) [49]. The original statistical plan
called for an interim analysis to be performed after 180 patients
completed the study. The 0.0294 level of signiﬁcance (using the
Pocock method [50]), which guided the Data Monitoring Com-
mittee with respect to study continuation, was not achieved in the
interim analysis [49]. In the interim analysis, the relationship
between ulcer duration at the time of screening and the incidence
of ulcer healing with Dermagraft® was analyzed based on the
results of a modiﬁed statistical plan, which indicated that (1) the
efﬁcacy analysis should be based only on patients with ulcers with
a duration of greater than six weeks at the time of the screening
visit, and (2) the primary endpoint should be analyzed using
Bayesian statistics. Furthermore, information obtained during the
initial part of the trial (the interim analysis) was utilized pro-
spectively in the latter part in order to estimate overall efﬁcacy (in
the ﬁnal analysis). Additional patients were enrolled until the
required endpoint of the Bayesian sequential procedure was
achieved (98.4% probability of beneﬁt) [49]. A diagram of the
required patient numbers and actual numbers enrolled in the trial
is shown in Fig. 2. Although 314 patients were enrolled in the
study, only 245 patients exhibited ulcers with a duration of
greater than six weeks were included in the ﬁnal analysis. Based
on the Bayesian analysis, the probability that Dermagraft® plus
conventional therapy increased the chance of achieving wound
closure in patients with ulcers with a duration of greater than six
weeks over that of conventional therapy alone was 98.4%.
Although the original sample size calculated using Fisher's exact
Table 1
Summary of pivotal study designs for evaluating the efﬁcacy of human cells and tissue products.a
Product name
(Category, approval
date, authorities)
Indication Study/Design Sample size Primary endpoint Results of the primary endpoint
US
Dermagraft-TCTM (PMA,
March 18, 1997, FDA/
CDRH)
For use as a temporary wound
covering for surgically excised full-
thickness and deep partial-
thickness thermal burn wounds in
patients prior to autograft
placement
Randomized, controlled, within-
patient, unmasked
66 (within-patient control) % Autograft “take” at days.
(Comparison with st rd care:
cryopreserved cadav lograft)
Signiﬁcantly equivalent to that of
wounds treated with allografts
(94.7% for Dermagraft-TCTM vs.
93.1% for frozen cadaver allografts
(control), p ¼ 0.0001)
Carticel™ (BLA, August
22, 1997, FDA/CBER)
For the repair of clinically
signiﬁcant, symptomatic, and
cartilaginous defects of the femoral
condyle (medical, lateral, or
trochlear) caused by acute or
repetitive trauma
1. Swedish retrospective clinical
study:
1) Retrospective case report forms
2) Questionnaire
3) Biopsy date (n ¼ 25)
153 (consecutive patients)
Principle evaluation: 82
with responses to the
questionnaire
Clinical outcome by uestion,
“how does your knee l now
compared to before ery?”
Patient questionnaire: 70% reported
an improved status
2. U.S. registry data base 191 (completion of 12-
month follow-up: 38)
Rating of the modiﬁe ncinnati
Knee Rating System linicians
and patients (Score 8 : Resumed
all activities)
12-month score of 8 or higher: 30%
(11/37)
No improvement: 19% (7/37)
Apligraf™/Graftskin
(PMA, May 28, 1998,
FDA/CDRH)
For use with standard therapeutic
compression for the treatment of
non-infected partial and full-
thickness skin ulcers due to venous
insufﬁciency of greater than 1
month duration andwhich have not
adequately responded to
conventional ulcer therapy
Prospective, randomized,
controlled, multi-specialty,
unmasked
161 (Apligraf™),
136 (Control)
Efﬁcacy:
130 (Apligraf™),
110 (Control)
1) The incidence of 1 would
closure per unit time d 2) The
overall incidence of 1 would
closure by 6 months
1) 50% patients achieved wound
closure: 140 days (Apligraf™) and
181 days (Control). (p ¼ 0.3916)
2) 55.4% (72/130, Apligraf™) and
49.1% (54/110, Control). (p ¼ 0.365)
Composite Cultured
Skin (HDE, February
21, 2001, FDA/CDRH)
For use in patients with mitten
hand deformity due to Recessive
Dystrophic Epidermolysis Bullosa
(RDEB) as an adjunct to standard
autograft procedures for covering
wounds and donor sites created
after the surgical release of hand
contractions
1. Australian clinical study: with-in
patient historical control
7 (historical control: 5) Duration of digital fu onality The use of CCS and autografts did
not decrease the time to re-surgery
Healing in Composite tured Skin
(CCS) treatment of d sites
When CCS was used, the need for
donor sites was reduced. In
addition, CCS-treated donor sites
healed without complications
2. United States clinical study:
within-patient controlled,
randomized
12 (within-patient control)
1) CCS
2) Collagen sponge
3) Standard care
The incidence or tim wound
healing in compariso CCS, the
acellular sponge and dard non-
adherent dressing at time point
No signiﬁcant differences
Orcel™ (PMA, August
31, 2001, FDA/CDRH)
For the treatment of fresh, clean
split thickness donor site wounds in
burnt patients
Multicenter, randomized, within-
patient controlled
82 The time (days) to w d closure
(100% re-epithelializ )
15 days for Orcel™ vs. 22 days for
the Control, for the ITT population,
median days to 100% wound
closure (p ¼ 0.0006, Log-Rank test)
Dermagraft® (PMA,
September 28, 2001,
FDA/CDRH)
For use for the treatment of full-
thickness diabetic foot ulcers of
greater than six weeks duration
which extend though the dermis,
but without tendon, muscle, joint
capsule, or bone exposure
1. Randomized, controlled, masked
(Pivotal I)
139 (Dermagraft®)
142 (Control)
Number of patients r ed
complete wound clo by 12
weeks
30% (42/139, Dermagraft®) and 28%
(40/142, control) in ITT analysis
2. Randomized, controlled, masked
(Pivotal II)
163 (Dermagraft®)
151 (Control)
Efﬁcacy:
130 (Dermagraft®)
115 (Control)
Complete wound clo by 12
weeks
Bayesian analysis: 98.4% probability
Dermagraft® plus conventional
therapy increased the chance of
closure
Epicel® (HDE, October
25, 2007, FDA/CDRH)
For use in patients who have deep
dermal or full-thickness burns
comprising a total body surface area
of greater than or equal to 30%
Physician-sponsored study:
prospective, single-centered,
controlled, randomized
20 (Standard Care plus
Epicel®),
24 (Standard care only)
Mortality Mortality*: 10.0% for Epicel® vs.
62.0% for Standard Care only
*Signiﬁcant in the original article
(continued on next page)
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Table 1 (continued )
Product name
(Category, approval
date, authorities)
Indication Study/Design Sample size Primary endpoint Results of the primary endpoint
Provenge® (BLA, April
29, 2010, FDA/CBER)
For the treatment of asymptomatic
or minimally symptomatic
metastatic castrate-resistant
(hormone refractory) prostate
cancer
Phase 3: randomized, double-blind,
placebo-controlled
341 (Provenge®)
171 (Placebo)
Overall survival Median survival (months)
Sipuleucel-T (Provenge®): 25.8
Placebo: 21.7 (p ¼ 0.032)
Laviv® (BLA, June 21,
2011, FDA/CBER)
For improvements of the
appearance of moderate to severe
nasolabial fold wrinkles in adults
Two Phase 3, multicenter, double
blind, controlled
1. IT-R-005
100 (Laviv®)
103 (Vehicle)
1) Two-point improvement in the
Evaluator Wrinkle Severity
Assessment (6-point scale)
2) Two-point improvement in the
Subject Wrinkle Assessment (5-
point scale)
- Subject assessment: 57% for
Laviv® vs. 30% for Control,
(p ¼ 0.0001)
- Physician Assessment: 33% for
Laviv® vs. 7% for Control,
(p < 0.0001)
2. IT-R-006
110 (Laviv®)
108 (Placebo)
- Subject assessment: 45% for
Laviv® vs. 18% for Control,
(p < 0.0001)
- Physician Assessment: 19% for
Laviv® vs. 7% for Control,
(p ¼ 0.0075)
Gintuit (BLA, March 9,
2012, FDA/CBER)
For topical (non-submerged)
application to a surgically created
vascular wound bed in the
treatment of mucogingival
conditions in adults. Gintuit is not
intended to provide root coverage
Prospective, randomized, within-
subject controlled
96
Efﬁcacy: 85
Percentage of Gintuit sites with KT*
2 mm at six months, compared to
a 50% success rate, in a single-arm
comparison
* keratinized tissue
95.3% met success criteria at
Gintuit, (p < 0.001**)
Exact binomial 95% CI (88.4, 98.7)
**: Comparison to a pre-deﬁned
standard of 50% of subjects with KT
width 2 mm
EU
ChondroCelect® (ATMP,
October 5, 2009,
EMA/CHMP)
For use in the repair of single
symptomatic cartilage defects of
the femoral condyle of the knee
(International Cartilage Repair
Society [ICRS] grade III or IV) in
adults
Phase 3, multicenter, randomized,
controlled
57 (ChondroCelect®)
61 (Microfracture (Active
comparator))
Superiority on the structural repair
(histology) endpoint at 12 months
and non-inferiority on the clinical
endpoint (change from baseline in
KOOS) for the average of the 12- to
18-month follow-up data
Differences in the endpoint:
- Histomorphometric 0.26
(p ¼ 0.003)
- ICRSII at 12 months 10.92
(p ¼ 0.0103)
Change in KOOS at 12 and 18
months 1.81 (no signiﬁcant
differences)
MACI (ATMP, June 27,
2013, EMA/CHMP)
For use in the repair of
symptomatic, full-thickness
cartilage defects of the knee (grade
III and IV of the Modiﬁed
Outerbridge Scale) of 3e20 cm2 in
skeletally mature adult patients
Prospective, randomized, open-
label, parallel-group, multicenter
72 (MACI)
72 (Microfracture (Active
comparator)
Change from baseline to Week 104
for the patient's Knee injury and
KOOS pain and function (Sports and
Recreational Activities [SRA]) scores
Difference LS (least squares) means:
- Pain 11.76 (P < 0.001)
- Function 11.41 (P < 0.001)
Provenge (ATMP,
September 6, 2013,
EMA/CHMP)
For the treatment of asymptomatic
or minimally symptomatic
metastatic (non-visceral) castrate-
resistant prostate cancer in male
adults in whom chemotherapy is
not yet clinically indicated
Randomized, double-blind,
controlled, multicenter
341 (Provenge)
171 (Placebo)
Overall survival Median survival (months)
Provenge: 25.8
Placebo: 21.7
(p ¼ 0.032)
Holoclar (ATMP,
February 17, 2015
EMA/CHMP)
For the treatment of adult patients
with a moderate to severe limbal
stem cell deﬁciency (deﬁned by the
presence of superﬁcial corneal
neovascularization in at least two
corneal quadrants, with central
corneal involvement, and severely
impaired visual acuity), unilateral
or bilateral, due to physical or
chemical ocular burns
Retrospective, non-randomized,
uncontrolled, case series-based
observational
104 ACLSCT success (success of
transplantation)
ACLSCT success (rate %): 75 (72.1%)
(p < 0.001), 95% CI (62.5, 86.5)
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JACE (Medical device,
October 29, 2007,
MHLW/PMDA)
For use in patients with serious,
extensive burns when sufﬁcient
donor sites for autologous skin graft
are not available and the total area
of deep dermal and full-thickness
burns is 30% or the total surface
area
Multi-center, open-label,
uncontrolled
2 Formation of epidermis at 4 weeks,
scoring from 1 to 4
Very effective: 1 (50%)
Effective: 1 (50%)
JACC (Medical device,
July 27, 2012,
MHLW/PMDA)
To alleviate clinical symptoms of
the traumatic cartilage deﬁciency
and osteochondritis dissecans
(excluding knee osteoarthritis) in
the knee joints with a cartilage-
defective area of 4 cm2 or more for
which there are no other options
Prospective, multi-center, non-
randomized, uncontrolled
30 Composite endpoint with
functional improvement in the
knee and arthroscopic evaluation
(ICRS score)
Very effective: 25 (83.3%)
Effective: 3 (10%)
Neither: 2 (2%)
Not effective: 0 (0.0%)
Temcell® HS Inj.
(Regenerative
medicine product,
September 18, 2015,
MHLW/PMDA)
For the treatment of acute graft-
versus-host disease (GVHD)
following hematopoietic stem cell
transplant
Single-arm, open-label, phase 2-3 25 Complete response continued for
28 days post treatment
48% (12/25 cases, 95% CI: 27.8, 68.7)
HeartSheet®
(Regenerative
medicine product,
September 18, 2015,
MHLW/PMDA)
For use in treatment of severe HF
(heart failure) caused by ischemic
heart disease, despite maximal
standard-of-care drug and
interventional therapies meeting
satisfying all conditions:
- New York Heart Association
(NYHA): class III or IV
- A left ventricular ejection fraction
(LVEF) 35% on resting
Single-arm, open-label, phase 2 7 The change in LVEF on gated
equilibrium blood-pool
scintigraphy from pre-
transplantation to 26 weeks post-
transplantation
Improved: 0
Unchanged: 5
Worsened: 2
ACLSCT, Autologous Cultured Limbal Stem Cell Transplantation; ATMP, Advanced Therapy Medical Products; BLA, Biologics License Application; CBER, Center of Biologics Evaluation and Research; CDRH, Center of Device and
Radiological Health; CHMP, Committee for Human Medicinal Products; EMA, European Medicines Agency; EU, European Union; FDA; Food and Drug Administration; HDE, the Humanitarian Device Exemption; ICRS, Inter-
national Cartilage Repair Society; IDE, Investigational Device Exemption; ITT, Intention-To-Treat; KOOS, Knee injury and Osteoarthritis Outcome Score; LVEF, left ventricular ejection fraction; MHLW, Ministry of Health, Labor
and Welfare; PMDA, Pharmaceuticals and Medical Devices Agency; US, the United States.
a The following six cord blood products are also approved in the US, but were excluded from the study owing to a lack of clinical studies or trials that solely examined the product: Hemacord (BLA, Nov. 10, 2011, CBER), HPC
Cord blood (BLA, May 24, 2012, CBER), Ducord (BLA, Oct. 3, 2012, CBER), Allocord (BLA, May 30, 2013, CBER), HPC Cord blood (BLA, June 13, 2013, CBER), and HPC cord blood (BLA, January 28, 2016, CEBER).
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Interim analysis and 
stratification
Identified  limited 
indication (Ulcer 
duration: more than 6
weeks)
Final enrollments
Analyzed with 
Bayesian statistics
Enrollment 
total: 314 
patients
Analyzed 
total: 245 
patients
Continued to enroll 
up to 180 patients
Up to 330 patients (165 patients per group)
180 patients completed
141 patients analyzed
Interim 141 patients
Interim 141 patients Additional 104 patients
Fig. 2. Schematic diagram for the planning and actual enrollment in Pivotal Study II of Dermagraft®. The diagram shows the required patient numbers and actual numbers
enrolled in the trial. Based on a Bayesian analysis, the probability that Dermagraft® plus conventional therapy increased the chance of achieving wound closure in patients with
ulcers with a duration of greater than six weeks over that of conventional therapy alone was 98.4%. Although the original sample size calculated using Fisher's exact test (i.e.,
frequentist statistics) was 330, the number of patients enrolled in the study was 314.
Original sample size: up to 330 patients
Major inclusion criteria: 
• Ulcer duration: more than 2 weeks
• Ulcer size: ≥ 1.0 cm2 to ≤ 20 cm2
Enrollment
Stratified by ulcer size
Randomization
Dermagraft® Control
Interim analysis
Additional 
enrollment
After 180 patients completed 
the study
Dermagraft ® (N=130) Control (N=115)
Group 1, ≥ 1 to ≤ 2 cm2 Group 2, > 2 to ≤ 20 cm2
Final analysis
N=245
Ulcer duration: more than 6 weeks
Require > 60 additional patients by Bayesian statistics  
Up to 180 patients with more than 6 weeks of ulcer 
duration 
Fig. 1. Study design and ﬂow diagram of patient enrollment in Pivotal Study II for Dermagraft. The original sample size was calculated using a two-group Fisher's exact test
with a 0.0294 one-sided signiﬁcance level and at least 80% power, indicating a required sample size of up to 330 patients for the Dermagraft® and control groups (1:1) when
designing the study (Mason, 2000) [49]. At randomization, study ulcers were stratiﬁed into one of two groups according to ulcer size: Group 1, 1 to 2 cm2; Group 2, >2 to
20 cm2. Within the two strata, patients were randomized into either the Dermagraft® or control group. The original statistical plan called for an interim analysis after 180 patients
completed the study. In the analysis, the relationship between ulcer duration at the time of screening and the incidence of ulcer healing with Dermagraft® was analyzed, as the
results of a modiﬁed statistical plan speciﬁed that (1) the efﬁcacy analysis included only on patients with ulcers with a duration of greater than 6 weeks at the time of the screening
visit and (2) the primary endpoint was analyzed using Bayesian statistics. Additional patients were enrolled until the required endpoint for the Bayesian sequential procedure was
achieved (98.4% probability of beneﬁt). Although 314 patients were enrolled in the study, only 245 patients exhibited ulcers with a duration of greater than six weeks were
incorporated in the ﬁnal analysis.
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tients enrolled in the study was 314.
The authority concluded that the study provided reasonable
evidence for the efﬁcacy of Dermagraft® in the treatment of full-
thickness diabetic foot ulcers with a duration of greater than six
weeks, in addition to the assurance of safety from all studies asfollows: the probability that Dermagraft® plus conventional ther-
apy provided a treatment beneﬁt to patients with ulcers with a
duration of greater than six weeks that provided by conventional
therapy alone was 98.4%. Furthermore, there was a 95% probability
that the percentage of patients achieving wound closure with
Dermagraft® ranged between 22% and 38% and that the percentage
Y. Jokura et al. / Regenerative Therapy 5 (2016) 86e95 93of patients achieving wound closure with the control treatment
ranged between 12% and 26%. The inclusion criteria for efﬁcacy
endpoints were patients with diabetic ulcers for 6 weeks or longer
at the time of screening. Thus, the approved indication based on the
results of the clinical trial was changed to patients with diabetic
ulcers for 6 weeks or longer.
4. Discussion
As of the end of June 2016, 24 products were approved as human
cells and tissue products in the US, the EU, and Japan. The study
designs and product characteristics, such as the size of the target
population, indications, approval category (e.g., HDE), source of the
materials, and clinical expectations (e.g., performance), varied
markedly, and these properties may affect study designs. Among
human cells and tissue products approved under current regula-
tions in the US, some early products were approved based on only
clinical registry data in the US and with only a small number of
study cases. In Japan, three of four products were approved based
on a pilot or phase I/II studies lacking a hypothesis, and with a very
small number of cases from clinical trials, as shown in Table 1. In
order to support product development in the industry and to pro-
vide clinicians access to new human cells and tissue products, the
authorities in the US, the EU, and Japan have taken various mea-
sures, such as establishing regulations and providing guidance. In
the US, several guidance documents have been published with
recommendations regarding statistical designs for clinical trials of
human cells and tissue products. In Japan, new initiatives, including
new regulations for human cells and tissue products, were imple-
mented in 2014; two products, i.e., Temcell® HS Inj. and Heart-
Sheet®, were approved in September 2015 as regenerative
medicine products under these new regulations [51]. Furthermore,
HeartSheet® was approved under a conditional and time-limited
approval pathway, which is another new initiative dedicated to
the regenerative medicine product category under the new regu-
lations [52].
In our analysis of efﬁcacy evaluations, we found that the pivotal
study for Dermagraft® used a Bayesian statistical analysis to eval-
uate the product by incorporating the results of an interim analysis,
and the authority judged the product efﬁcacy based on these re-
sults. In the review of Dermagraft®, “prior information” from the
interim analysis was used for the ﬁnal analysis, which was
described as follows: Bayesian statistics allow for information ob-
tained during the initial part of a trial to be utilized prospectively in
the latter part in order to enable the overall estimation of measures
of efﬁcacy [29]. In addition, considering that frequentist statistics
were used for the ﬁrst pivotal study and Bayesian statistics were
used in the second pivotal study for product approval, it is bene-
ﬁcial to consider a ﬂexible trial design.
Bayesian statistics are suitable for clinical trials to evaluate
products, such as medical devices, because they are continuously
improved; “prior information” is necessary for the analysis and is
generally obtained during product development. Pennello et al.
[53] of the Division of Biostatistics of the FDA explained why device
trials are particularly well-suited to Bayesian analyses. “For
example, if a therapeutic device has evolved in relatively small
increments form previous generation of the same increments from
previous generations of the same type of device, then prior infor-
mation form the trials for the previous devices can be predicted of
the safety and effectiveness proﬁle of the new derive. The reason
the previous trials can be predictive is that themechanism of action
of a therapeutic device is often physical, implying a local effect that
is often predictable. In contrast, the mechanism of action of phar-
maceuticals is pharmacokinetic/pharmacodynamics, implying
systemic effect that are often unpredictable form similar but notidentical formulations.” Cells and tissue products that only affect or
impact local tissues and do not exert systemic effects, e.g., skin
substitutes, muscle substitutes, or cartilage substitutes, share
similar properties to medical devices; accordingly, we concluded
that prior information obtained from previous studies can be
applied to new studies in a Bayesian framework. Dermagraft® is
human ﬁbroblast-derived dermal substitute for the treatment of
diabetic foot ulcers, and it has primarily local effects (at the wound
site) [49]. This case study supports the feasibility of a Bayesian
approach for human cells and tissue products with similar prop-
erties to those of medical devices.
Methods that use information accrued during trials are adapt-
able, but they have various additional beneﬁts: accumulating re-
sults may provide a basis for modifying the design of the trial, e.g.,
by slowing (or stopping) or expanding accrual, altering randomi-
zation strategies to favor better-performing therapies, dropping or
adding treatment arms, and changing the trial population to focus
on patient subsets that are responding better to the experimental
therapies [8]. In addition to prior information obtained from the
interim analysis of the trial, “historical” information from the
source, such as clinical trials conducted overseas, patient registries,
clinical data obtained for very similar products, and pilot studies,
may be used according to the “Guidance for the Use of Bayesian
Statistics in Medical Device Clinical Trials” [7].
The FDA issued the guidance document on February 5, 2010 that
apply not only to medical device applications, but also to human
cells and tissue products approved as medical devices, such as
Dermagraft®. The objective of this guidance is to provide the least
burdensome way to evaluate submissions by the authority. The
guidance indicates that “the Bayesian approach, when correctly
employed, may be less burdensome than a frequentist approach.
Section 513(a) (3) of the Federal Food, Drug, and Cosmetic Act
(FFDCA) mandates that the FDA shall consider the least burden-
some appropriate means of evaluating efﬁcacy of a device that
would have a reasonable likelihood of resulting in approval” [7].
Between issuances of the draft and the ﬁnal guidance, the FDA held
a workshop in 2005 [54] and public meetings between 2006 and
2009 [55] to ensure that public input is reﬂected in the guidance. In
the period between 1999 and 2003, prior to the issuance of the
draft guidance in 2006, at least 14 original PMA and PMA Supple-
ments were approved by the FDA using a Bayesian primary analysis
[56]. Moreover, in the workshop in 2005, the FDA report titled
“Innovation or Stagnation: Challenges and Opportunities on the
Critical Path to Medical Product Development” was published,
which emphasized the need for intensiﬁed scientiﬁc efforts to
improve the development and evaluation of medical products [54],
resulting in the issuance of the guidance.
Two main points should be considered when applying Bayesian
statistics: 1) according to the guidance, prior information should be
discussed with the FDA prior to the initiation of a study, and 2)
indications of the device may be impacted by modiﬁcations at the
interim analysis. The former point describes a regulatory pathway
in the US for consultation with the FDA when designing clinical
studies, similar to the procedure for an IDE. In Japan, there is also a
consultation system with regulatory authority, PMDA, which is
used when designing clinical trials for regulatory approval pur-
poses [4]. Therefore, prior to ﬁnalizing a study design, it is neces-
sary to obtain alignments from regulatory authorities in the US and
Japan. The second consideration can be broadly applied, particu-
larly to studies using Bayesian statistics, if the results from an
interim analysis are used in the ﬁnal analysis. For example, if an
interim analysis limits the original indications, the ﬁnal indication
may also be limited, as demonstrated in the case of Dermagraft ®.
Bayesian statistics can be also useful for post-marketing studies,
since pre-marketing study results (information) could be used as
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ance also states the following [7]: “FDA believes the Bayesian
approach is well suited for surveillance purposes. The key concept:
“Today's posterior is tomorrow's prior” allows you to use the pos-
terior distribution from a pre-market study as a prior distribution
for surveillance purpose, to the extent that data from the clinical
study reﬂect how the device is used after approval. You may
continue to update post-market information via Bayes' theorem as
more data a gathered.”
Overall, the FDA guidance indicates that a sound Bayesian
approach could be less burdensome than a traditional statistical
approach [7]. However, some important lessons can be gained from
previous experiences. For example, Bayesian trials need to be
prospectively designed. It is never a good idea to switch from a
frequentist to Bayesian approach, or vice versa. Applicants need to
meet early and often with regulators, as noted above. Prior infor-
mation needs to be identiﬁed in advance. The control group cannot
be used as a source of prior information for a new product, espe-
cially if the objective is to show that the new product is not inferior.
The applicant needs to work with an expert Bayesian statistician.
Computing power is necessary for large-scale simulations. Valida-
tion and Quality Assurance are key components of the study
operation.
In the EU and Japan, although there were no speciﬁc guidance
documents for statistical methods, there was broader guidance for
clinical trials on medicinal products in which Bayesian statistics
were introduced. Since the ﬁnal pivotal study (Pivotal II) of Der-
magraft® was conducted between 1998 and 2000 [57], the study
was designed before the issuance of the guidance, and even before
the draft guidance was issued in 2006 [58]. Moreover, because the
guidance was only issued in 2010, it will be necessary to conduct
further analyses to determine whether this guidance is useful for
clinical investigations on human cells and tissue products and to
obtain product approval. However, based on a literature review of
clinical trials using Bayesian statistics published through
September 2011, most (67.2%) of the 122 studies utilized Bayesian
statistics for efﬁcacy evaluations [10], suggesting that Bayesian
statistics are appropriate for conﬁrming product efﬁcacy. Therefore,
it is reasonable to consider Bayesian statistics when designing
clinical investigations, depending on the characteristics and indi-
cation of the product, owing to its beneﬁts, such as a potentially
shorter study duration and smaller enrollment.
In addition to the statistical guidance, the FDA recently issued a
draft guidance regarding adaptive designs for clinical studies,
“Adaptive Designs of Medical Devices Clinical Studies,” which
supports the development of human cells and tissue products
based on the design of clinical investigations by “reducing resource
requirements and/or increasing the chance of study success” [46].
Considering the recent issuance of this guidance and draft guidance
for new statistical approaches in clinical studies, it may become a
powerful tool for designing clinical trials, and it has the potential to
accelerate the development of human cells and tissue products.
Considering guidance related to clinical trial statistics, such as
“Considerations for the Design of Early-Phase Clinical Trials of
Cellular and Gene Therapy Products” published in June 2015 [5], the
FDA aggressively supports sponsors or manufacturers for the
development of medical products, rather than other authorities.
In Japan, a new Regulatory Act named the “Pharmaceuticals and
Medical Devices Act” (PMD Act) was implemented in 2014, and a
new category was established, i.e., “regenerative medicine prod-
ucts,” in addition to drugs, medical devices, quasi-drugs, and cos-
metics [4]. Regenerative medicine products are deﬁned as products
based on processed human or animal cells intended for either a) the
reconstruction, repair, or formation of a structure or its function in
the human (or animal) body (i.e., tissue-engineered products) or b)the treatment or prevention of human (or animal) diseases (i.e., cell
therapy products), or articles intended for the treatment of diseases
in humans (or animals) that are transgenic for expression in human
(or animal) cells (i.e., gene therapy products). Speciﬁcally for the
new category, the PMD Act introduced conditional and time-
limited approvals. If safety is conﬁrmed and a probable beneﬁt of
the product is demonstrated by clinical trial(s), the product receives
conditional and time-limited approval. After obtaining this
approval, it is possible tomarket products; however, patient follow-
ups must be conducted in order to further conﬁrm product safety
and efﬁcacy, and data must be submitted to the authority for ﬁnal
approval [4]. In view of this new regulation, Bayesian statistics may
be useful. Speciﬁcally, premarket trial data can be incorporated as
prior information in a postmarket follow-up study to examine
effectiveness for the ﬁnal application for production and distribu-
tion after obtaining conditional and time-limited approval.
5. Study limitations
The survey focused on human cells and tissue products
currently approved in the US, EU, and Japan. The results of this
analysis are therefore limited by the small sample size of approved
products compared to the numbers of drugs and medical devices.
6. Conclusion
The use of a modern statistical approach, such as Bayesian sta-
tistics, and interim analyses (i.e., an adaptive design) may be
considered when evaluating the efﬁcacy of human cells and tissue
products in clinical trials, despite the difﬁculties associated with
these approaches. Interim analyses are beneﬁcial for identifying a
target patient population for a product. Similarly, new regulations
enabling conditional and time-limited approval in Japan promote
the use of Bayesian statistics in follow-up studies.
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